ASP Isotopes Targets >$300M EBITDA by 2031, Initiates Commercial Shipments of Key Isotopes in 2026
ASPI is trading near its 52-week low of $3.92 (13% above the low).
Summary
ASP Isotopes announced a comprehensive business update, projecting over $300 million in EBITDA by 2031 and confirming first commercial shipments of key isotopes in 2026, alongside significant progress in its Helium project and radiopharmacy expansion.
Key Events · Earnings and Guidance · ASPI
-
Ambitious Long-Term EBITDA Target Set
The company announced a long-term EBITDA target of greater than $300 million by 2031, signaling strong growth expectations.
-
First Commercial Shipments Expected in 2026
ASP Isotopes anticipates initial commercial shipments of enriched Silicon-28, Carbon-14, and Ytterbium-176 across its nuclear medicine and electronics platforms in 2026.
-
Helium Project Phase 1 Nears Completion
Phase 1 drilling at the Virginia Gas Project was completed four months ahead of schedule, with nameplate capacity for Helium expected in Q3 2026.
-
Radiopharmacy Operations Expand with US Acquisitions
The company acquired two independent radiopharmacies in Florida and South Carolina, targeting over $10 million in revenue from this segment in 2026, approximately double 2025 reported revenue.
Analysis · ASPI · Industrial Applications And Services
ASP Isotopes provided a comprehensive business update, outlining significant operational milestones and an ambitious long-term financial target. The company expects first commercial shipments of Silicon-28, Carbon-14, and Ytterbium-176 in 2026, marking a critical transition from development to commercialization across its nuclear medicine and electronics platforms. Additionally, the company anticipates achieving Phase 1 nameplate capacity for its Helium project in Q3 2026, following ahead-of-schedule drilling. The long-term EBITDA target of over $300 million by 2031, while ambitious given current revenues, signals strong management confidence in future growth. The company's robust cash position of $333 million as of December 31, 2025, provides substantial runway for these initiatives, despite the previously reported net loss for 2025. The expansion of radiopharmacy operations through U.S. acquisitions and a target to double revenue in this segment further supports the growth narrative.
At the time of this filing, ASPI was trading at $4.44 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $560.5M. The 52-week trading range was $3.92 to $14.49. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.